Alcon/$ALC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Geneva, Switzerland
Employees
25,000
ISIN
CH0432492467
Website
Alcon Metrics
BasicAdvanced
$44B
39.61
$2.25
0.75
$0.18
0.20%
Price and volume
Market cap
$44B
Beta
0.75
52-week high
$99.64
52-week low
$80.48
Average daily volume
1.8M
Dividend rate
$0.18
Financial strength
Current ratio
2.701
Quick ratio
1.455
Long term debt to equity
22.821
Total debt to equity
23.634
Dividend payout ratio (TTM)
11.61%
Interest coverage (TTM)
6.78%
Management effectiveness
Return on assets (TTM)
2.74%
Return on equity (TTM)
5.23%
Valuation
Price to earnings (TTM)
39.608
Price to revenue (TTM)
4.442
Price to book
1.64
Price to tangible book (TTM)
10.45
Price to free cash flow (TTM)
30.344
Dividend yield (TTM)
0.20%
Forward dividend yield
0.20%
Growth
Revenue change (TTM)
3.80%
Earnings per share change (TTM)
6.65%
3-year revenue growth (CAGR)
5.10%
3-year earnings per share growth (CAGR)
34.24%
3-year dividend per share growth (CAGR)
12.09%
What the Analysts think about Alcon
Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Alcon Financial Performance
Revenues and expenses
Alcon Earnings Performance
Company profitability
Alcon News
AllArticlesVideos
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
Business Wire·1 week ago
US FDA approves Alcon's new dry-eye drug
Reuters·2 weeks ago
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alcon stock?
Alcon (ALC) has a market cap of $44B as of June 13, 2025.
What is the P/E ratio for Alcon stock?
The price to earnings (P/E) ratio for Alcon (ALC) stock is 39.61 as of June 13, 2025.
Does Alcon stock pay dividends?
Yes, the Alcon (ALC) stock pays dividends to shareholders. As of June 13, 2025, the dividend rate is $0.182 and the yield is 0.2%. Alcon has a payout ratio of 11.61% on a trailing twelve-month basis.
When is the next Alcon dividend payment date?
The next Alcon (ALC) dividend payment date is unconfirmed.
What is the beta indicator for Alcon?
Alcon (ALC) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.